References
- O’Rahilly S. Human genetics illuminates the paths to metabolic disease. Nature19, 307–314 (2009).
- Friedman JM. Obesity: causes and control of excess body fat. Nature21, 340–342 (2009).
- Hotamisligil GS. Inflammation and metabolic disorders. Nature14, 860–867 (2006).
- Bastard JP, Maachi M, Lagathu C et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur. Cytokine Netw.17, 4–12 (2006).
- Gao Q, Horvath TL. Neuronal control of energy homeostasis. FEBS Lett.9, 132–141 (2008).
- Dietrich MO, Horvath TL. Feeding signals and brain circuitry. Eur. J. Neurosci.30, 1688–1696 (2009).
- Horvath TL, Bruning JC. Developmental programming of the hypothalamus: a matter of fat. Nat. Med.12, 52–53 (2006).
- Abizaid A, Gao Q, Horvath TL. Thoughts for food: brain mechanisms and peripheral energy balance. Neuron21, 691–702 (2006).
- Horvath TL. The hardship of obesity: a soft-wired hypothalamus. Nat. Neurosci.8, 561–565 (2005).
- La Cava A, Matarese G. The weight of leptin in immunity. Nat. Rev. Immunol.4, 371–379 (2004).
- Symonds ME, Sebert SP, Hyatt MA, Budge H. Nutritional programming of the metabolic syndrome. Nat. Rev. Endocrinol.5, 604–610 (2009).
- Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol. Cell. Endocrinol.15, 1–16 (2010).
- Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature372, 425–432 (1994).
- Tartaglia LA, Dembski M, Weng X et al. Identification and expression cloning of a leptin receptor, Ob-R. Cell83, 1263–1270 (1995).
- Montague CT, Farooqi IS, Whitehead JP et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature387, 903–908 (1997).
- Clément K, Vaisse C, Lahlou N et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature392, 398–401 (1998).
- Krude H, Biebermann H, Luck W, Horn R, Brabant G, Grüters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat. Genet.19, 155–157 (1998).
- Jackson RS, Creemers JW, Ohagi S et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat. Genet.16, 303–306 (1997).
- Vaisse C, Clement K, Guy-Grand B, Froguel P. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat. Genet.20, 113–114 (1998).
- Yeo GS, Farooqi IS, Aminian S, Halsall DJ, Stanhope RG, O’Rahilly S. A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat. Genet.20, 111–112 (1998).
- Holder JL Jr, Butte NF, Zinn AR. Profound obesity associated with a balanced translocation that disrupts the SIM1 gene. Hum. Mol. Genet.9, 101–108 (2000).
- Bochukova EG, Huang N, Keogh J et al. Large, rare chromosomal deletions associated with severe early-onset obesity. Nature463, 666–670 (2010).
- Hotamisligil GS, Spiegelman BM. Tumor necrosis factor α: a key component of the obesity-diabetes link. Diabetes43, 1271–1278 (1994).
- Spiegelman BM, Hotamisligil GS. Through thick and thin: wasting, obesity, and TNF α. Cell73, 625–627 (1993).
- Bullo M, García-Lorda P, Megias I, Salas-Salvadó J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes. Res.11, 525–531 (2003).
- Rasouli N, Kern PA. Adipocytokines and the metabolic complications of obesity. J. Clin. Endocrinol. Metab.93, 64–73 (2008).
- MacLaren R, Cui W, Cianflone K. Adipokines and the immune system: an adipocentric view. Adv. Exp. Med. Biol.632, 1–21 (2008).
- Dixit VD. Adipose–immune interactions during obesity and caloric restriction: reciprocal mechanisms regulating immunity and health span. J. Leukoc. Biol.84, 882–892 (2008).
- Bilan PJ, Samokhvalov V, Koshkina A, Schertzer JD, Samaan MC, Klip A. Direct and macrophage-mediated actions of fatty acids causing insulin resistance in muscle cells. Arch. Physiol. Biochem.115, 176–190 (2009).
- Bourlier V, Bouloumie A. Role of macrophage tissue infiltration in obesity and insulin resistance. Diabetes Metab.35, 251–260 (2009).
- Yang R, Trevillyan JM. c-Jun N-terminal kinase pathways in diabetes. Int. J. Biochem. Cell. Biol.40, 2702–2706 (2008).
- Ruan H, Pownall HJ. The adipocyte IKK/NFκB pathway: a therapeutic target for insulin resistance. Curr. Opin. Investig. Drugs10, 346–352 (2009).
- Kleinridders A, Schenten D, Könner AC et al. MyD88 signaling in the CNS is required for development of fatty acid-induced leptin resistance and diet-induced obesity. Cell Metab.10, 249–259 (2009).
- Wisse BE, Schwartz MW. Does hypothalamic inflammation cause obesity? Cell Metab.10, 241–242 (2009).
- Nishimura S, Manabe I, Nagasaki M et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat. Med.15, 914–920 (2009).
- Liu J, Divoux A, Sun J et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat. Med.15, 940–945 (2009).
- Shah TJ, Leik CE, Walsh SW. Neutrophil infiltration and systemic vascular inflammation in obese women. Reprod. Sci.17, 116–124 (2009).
- Ohmura K, Ishimori N, Ohmura Yet al. Natural killer T cells are involved in adipose tissues inflammation and glucose intolerance in diet-induced obese mice. Arterioscler. Thromb. Vasc. Biol.30, 193–199 (2009).
- Moro K, Yamada T, Tanabe M et al. Innate production of T(h)2 cytokines by adipose tissue-associated c-Kit(+)Sca-1(+) lymphoid cells. Nature463, 540–544 (2009).
- Lumeng CN, Maillard I, Saltiel AR. T-ing up inflammation in fat. Nat. Med.15, 846–847 (2009).
- Feuerer M, Herrero L, Cipolletta D et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat. Med.15, 930–399 (2009).
- Winer S, Chan Y, Paltser G et al. Normalization of obesity-associated insulin resistance through immunotherapy. Nat. Med.15, 921–929 (2009).
- Sterry W, Strober BE, Menter A. Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br. J. Dermatol.157, 649–655 (2007).
- Radetti G, Kleon W, Buzi F et al. Thyroid function and structure are affected in childhood obesity. J. Clin. Endocrinol. Metab.93, 4749–4754 (2008).
- Munger KL, Chitnis T, Ascherio A. Body size and risk of MS in two cohorts of US women. Neurology73, 1543–1550 (2009).
- Fessler MB, Rudel LL, Brown JM. Toll-like receptor signaling links dietary fatty acids to the metabolic syndrome. Curr. Opin. Lipidol.20, 379–385 (2009).
- Horvath TL, Andrews ZB, Diano S. Fuel utilization by hypothalamic neurons: roles for ROS. Trends Endocrinol. Metab.20, 78–87 (2009).
- Hotamisligil GS. Inflammation and endoplasmic reticulum stress in obesity and diabetes. Int. J. Obes. (Lond.)32, 52–54 (2008).
- Chang-Chen KJ, Mullur R, Bernal-Mizrachi E. β-cell failure as a complication of diabetes. Rev. Endocr. Metab. Disord.9, 329–343 (2008).
- Ahmed M, Gaffen SL. IL-17 in obesity and adipogenesis. Rev. Cytokine Growth Factor21, 449–453 (2010).
- Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol.22, 531–562 (2004).
- Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol.11, 7–13 (2009).
- Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol.6, 345–352 (2005).
- Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science299, 1057–1061 (2003).
- Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol.4, 330–336 (2003).
- Stephens GL, Shevach EM. Foxp3+ regulatory T cells: selfishness under scrutiny. Immunity27, 417–419 (2007).
- Petrausch U, Poehlein CH, Jensen SM. Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. Curr. Mol. Med.9, 673–682 (2009).
- Wildin RS, Freitas A. IPEX and FOXP3: clinical and research perspectives. J. Autoimmun.25, 56–62 (2005).
- Bennett CL, Ochs HD. IPEX is a unique X-linked syndrome characterized by immune dysfunction, polyendocrinopathy, enteropathy, and a variety of autoimmune phenomena. Curr. Opin. Pediatr.13, 533–538 (2001).
- De Rosa V, Procaccini C, Calì G et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity26, 241–255 (2007).
- Taleb S, Tedgui A, Mallat Z. Regulatory T-cell immunity and its relevance to atherosclerosis. J. Intern. Med.263, 489–499 (2008).
- Taleb S, Herbin O, Ait-Oufella H et al. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arterioscler. Thromb. Vasc. Biol.27, 2691–2698 (2007).
- Matarese G, Carrieri PB, La Cava A et al. Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25+ regulatory T cells. Proc. Natl Acad. Sci. USA102, 5150–5155 (2005).
- Johansson C, Samuelsson U, Ludvigsson J. A high weight gain in early life is associated with an increased risk of Type 1 (insulin-dependent) diabetes. Diabetologia37, 91–94 (1994).
- Hypponen E, Virtanen SM, Kenward MG, Knip M, Akerblom HK. Obesity, increased linear growth, and risk of Type 1 diabetes in children. Diabetes Care23, 1755–1760 (2000).
- Bruining GJ. Association between infant growth before onset of juvenile Type-1 diabetes and autoantibodies to IA-2. Lancet356, 655–656 (2000).
- Kibirige M, Metcalf B, Renuka R, Wilkin TJ. Testing the accelerator hypothesis: the relationship between body mass and age at diagnosis of Type 1 diabetes. Diabetes Care26, 2865–2870 (2003).
- Betts P, Mulligan J, Ward P, Smith B, Wilkin TJ. Increasing body weight predicts the earlier onset of insulin-dependant diabetes in childhood: testing the ‘accelerator hypothesis’. Diabet. Med.22, 144–151 (2005).
- Knerr I, Wolf J, Reinehr T et al. The ‘accelerator hypothesis’: relationship between weight, height, body mass index and age at diagnosis in a large cohort of 9248 German and Austrian children with Type 1 diabetes mellitus. Diabetologia48, 2501–2504 (2005).
- Kordonouri O, Hartmann R. Higher body weight is associated with earlier onset of Type 1 diabetes in children: confirming the ‘accelerator hypothesis’. Diabet. Med.22, 1783–1784 (2005).
- Wilkin TJ. The accelerator hypothesis: a review of the evidence for insulin resistance as the basis for Type I as well as Type II diabetes. Int. J. Obes. (Lond.)33, 716–726 (2009).
- Xu P, Krischer JP, Cuthbertson D, Greenbaum C, Palmer JP. Role of insulin resistance in predicting progression to Type 1 diabetes. Diabetes Care30, 2314–2320 (2007).
- Fourlanos S, Harrison LC, Colman PG. The accelerator hypothesis and increasing incidence of Type 1 diabetes. Curr. Opin. Endocrinol. Diabetes Obes.15, 321–325 (2008).
- Fourlanos S, Narendran P, Byrnes GB, Colman PG, Harrison LC. Insulin resistance is a risk factor for progression to Type 1 diabetes. Diabetologia47, 1661–1667 (2004).
- Hawa MI, Bonfanti R, Valeri C, Delli Castelli M, Beyan H, Leslie RD. No evidence for genetically determined alteration in insulin secretion or sensitivity predisposing to Type 1 diabetes: a study of identical twins. Diabetes Care28, 1415–1418 (2005).
- Dahlquist G. Can we slow the rising incidence of childhood-onset autoimmune diabetes? The overload hypothesis. Diabetologia49, 20–24 (2006).
- Libman IM, Sun K, Foley TP, Becker DJ. Thyroid autoimmunity in children with features of both Type 1 and Type 2 diabetes. Pediatr. Diabetes9, 266–271 (2008).
- Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat. Rev. Immunol.9, 324–337 (2009).
- Nath N, Khan M, Paintlia MK. Metformin attenuated the autoimmune disease of the central nervous system in animal models of multiple sclerosis. J. Immunol.182, 8005–8014 (2009).
- Yang X, Smith U. Adipose tissue distribution and risk of metabolic disease: does thiazolidinedione-induced adipose tissue redistribution provide a clue to the answer? Diabetologia50, 1127–1139 (2007).
- Hill MJ, Metcalfe D, McTernan PG. Obesity and diabetes: lipids, ‘nowhere to run to’. Clin. Sci. (Lond.)116, 113–123 (2009).
- Klotz, L. Burgdorf S, Dani I et al. The nuclear receptor PPAR γ selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity. J. Exp. Med.206, 2079–2089 (2009).
- Zhang X, Markovic-Plese S. Statins’ immunomodulatory potential against Th17 cell-mediated autoimmune response. Immunol. Res.41, 165–174 (2008).
- Araújo EP, Torsoni MA, Velloso LA. Hypothalamic inflammation and obesity. Vitam. Horm.82, 129–143 (2010).